Supplementary Figures S1-S16 from NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2025-12-11
Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer
Acta Oncologica · 2025-11-18 · 2 citations
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study
Annals of Oncology · 2025-10-17 · 12 citations
PL02.15 Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic ROS1+ NSCLC
Journal of Thoracic Oncology · 2025-10-01 · 3 citations
Durable response with mutation-guided <i>ALK</i> inhibition in a patient with metastatic epithelioid inflammatory myofibroblastic sarcoma: A case report
Rare Tumors · 2025-10-01
EP.12.23 Disease Burden and rwPFS as a Surrogate Endpoint for rwOS in NTRK+ NSCLC and Other Advanced/Metastatic Solid Tumors
Journal of Thoracic Oncology · 2025-10-01
972P Neladalkib (NVL-655) efficacy and safety in patients with ALK-positive solid tumors in the ALKOVE-1 study
Annals of Oncology · 2025-09-01
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma
Nature Communications · 2025-08-19 · 9 citations
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer
JAMA Network Open · 2025-07-15 · 19 citations
Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center
Frontiers in Oncology · 2025-07-15
Characteristics of Short-Term Survivors With ALK or ROS1-Altered Metastatic NSCLC
JTO Clinical and Research Reports · 2025-07-03
Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase Inhibitors
JTO Clinical and Research Reports · 2025-07-01
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status
Clinical Lung Cancer · 2025-06-05 · 1 citations
Integrated Molecular and Clinical Characterization of Pulmonary Large Cell Neuroendocrine CarcinomaPreprint
Research Square · 2025-05-16
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation
Cell Reports Medicine · 2025-05-01 · 4 citations
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
Lung Cancer · 2025-04-19 · 5 citations
PP01.03 Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC
Journal of Thoracic Oncology · 2025-04-01
Supplemental Table 1 from Development, Review, and Activation of Thoracic Oncology Investigator-Initiated TrialsPreprint
2025-03-17
Supplemental Figure 1 from Development, Review, and Activation of Thoracic Oncology Investigator-Initiated TrialsPreprint
2025-03-17
Supplemental Table 3 from Development, Review, and Activation of Thoracic Oncology Investigator-Initiated TrialsPreprint
2025-03-17